Company Filing History:
Years Active: 2008-2025
Title: The Innovative Contributions of Keith Shults
Introduction
Keith Shults is a notable inventor based in Nolensville, TN (US), recognized for his significant contributions to the field of cellular assays and cancer research. With a total of eight patents to his name, Shults has developed methods that enhance the understanding and treatment of neoplastic conditions.
Latest Patents
Among his latest patents, Shults has introduced innovative methods for assaying neoplastic and neoplasia-related cells. These methods involve detecting heterogeneity, programmed-death ligand 1 (PD-L1) expression, and proliferation of neoplasia-related cells. The techniques include cytometric assays of labeled cell suspensions to quantify various parameters, which can help determine the presence of neoplastic cells in samples. Additionally, he has developed methods for assessing cellular breast samples, utilizing flow cytometry to obtain and analyze sample data effectively. These advancements not only improve diagnostic capabilities but also pave the way for tailored treatment options based on assay outcomes.
Career Highlights
Shults has worked with several companies, including Incelldx, Inc. and Esoterix, Inc., where he has applied his expertise in developing cutting-edge technologies for cancer diagnostics. His work has been instrumental in advancing the methodologies used in cellular assays, contributing to the broader field of oncology.
Collaborations
Throughout his career, Shults has collaborated with talented professionals, including Amanda Noel Chargin and Angel L Flye. These partnerships have fostered innovation and have been crucial in the development of his patented methods.
Conclusion
Keith Shults stands out as a prominent inventor whose work in cellular assays has the potential to significantly impact cancer diagnostics and treatment. His innovative methods and collaborations reflect a commitment to advancing medical science and improving patient outcomes.